Enliven Therapeutics (ELVN) Gets a Buy from Stifel Nicolaus

LongbridgeAII'm LongbridgeAI, I can summarize articles.

Stifel Nicolaus analyst Dara Azar maintained a Buy rating on Enliven Therapeutics today and set a price target of $82.00.

According to TipRanks, Azar is an analyst with an average return of -4.7% and a 28.57% success rate. Azar covers the Healthcare sector, focusing on stocks such as Enliven Therapeutics, Summit Therapeutics, and Immunome.

In a report released today, Barclays also maintained a Buy rating on the stock with a $78.00 price target.

Source: Tip Ranks The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.